based on additional required services such as clinical trial evaluation or modifications to existing registrations.

• Fees for New Drug Registration: ₦150,000 – ₦500,000 depending on complexity.
• Fees for Generics: Approximately ₦100,000.
• Import License: Starts at ₦50,000.
• Manufacturing License: Varies widely, typically ₦200,000 – ₦1,000,000.

Once the application fee is paid, ensure you keep all payment receipts as they will be required for processing your application. For a full list of fees and guidelines, reference the NAFDAC official website.

Step 2: Preparing Your Dossier for Submission to NAFDAC

The dossier is a critical component in the submission process to NAFDAC. The compilation of the dossier must adhere to the guidelines established by NAFDAC which aligns with ICH regulatory standards. Understanding the structure and necessary components of the dossier is paramount to smooth regulatory submission and subsequent approval.

A well-prepared dossier typically includes the following sections:

• Administrative Information: This includes the company profile, product overview, and cover letters.
• Quality (CMC) Data: Detailed chemistry, manufacturing, and control (CMC) information regarding the pharmaceutical product.
• Preclinical Studies: Summaries of pharmacology and toxicology studies highlighting safety profiles.
• Clinical Studies: Data from clinical trials providing efficacy and safety data.
• Labeling: Mock-ups or drafts of product packaging and patient information leaflets.
• Pharmacovigilance Plan: Outline of plans for monitoring adverse reactions post-approval.

Ensure that the dossier is in compliance with NAFDAC guidelines, which can be reviewed through their official resources. Clarity and precision in this documentation will significantly influence the evaluation timeline.

Step 3: Submission of Your Dossier to NAFDAC

The submission process is a crucial step in the regulatory pathway. After ensuring that all components of the dossier are complete and in order, the next phase involves the submission to NAFDAC.

NAFDAC requires that all submissions be made electronically using their online submission portal, which necessitates prior registration. Here are key considerations:

• Online Registration: Create an account on the NAFDAC e-Portal to submit documents electronically.
• Document Formatting: All documents must be submitted in specified formats, typically including PDF or Word formats only.
• Submission Deadlines: Be aware of any submission deadlines and plan accordingly to avoid delays.

Upon submission, NAFDAC acknowledges receipt of the documents. Retain this acknowledgment as it may be requested later in the process.

Step 4: Evaluation of the Submission by NAFDAC

Following submission, NAFDAC initiates an evaluation of the dossier. The evaluation is multi-faceted and encompasses a comprehensive review of all submitted materials including the scientific data, manufacturing protocols, and safety assessments.

The typical evaluation timeline can vary based on several factors such as the complexity of the product, adherence to submission guidelines, and workload at NAFDAC. On average, the evaluation period ranges from 90 to 180 days. During this phase, regulators may request additional information or clarification.

• Questions for Clarification: Be prepared to respond promptly to any questions or requests from NAFDAC within the stipulated timeframe.
• Communication: Maintain clear communication via the e-Portal to track the progress of your application.

It is essential to understand that delays in communication or submission of required information can result in extended evaluation timelines, potentially influencing market entry plans.

Step 5: Approval Duration and Post-Approval Commitments

After a successful evaluation, NAFDAC grants approval, which allows the pharmaceutical product to be marketed in Nigeria. The approval duration can vary, but typically licensing takes approximately 30 days post-evaluation if there are no outstanding issues. However, post-approval commitments are equally crucial to maintain compliance.

Organizations must prepare to adhere to several post-approval obligations:

• Pharmacovigilance Requirements: Companies must implement a pharmacovigilance system for monitoring adverse effects as mandated by WHO guidelines.
• Periodic Safety Update Reports (PSURs): Submit regular reports detailing the safety data as identified during market use.
• Product Changes: Notify NAFDAC regarding any changes in formulation, manufacturing processes, or labeling.

Continued compliance with regulatory requirements is critical for maintaining the license to operate and avoid penalties or product recalls.

Step 6: Continuous Regulatory Engagement and Quality Assurance

Continuous engagement with regulatory authorities and an emphasis on quality assurance throughout the lifecycle of the product must be prioritized. These engagements involve maintaining relationships with NAFDAC and understanding any evolving regulations or guidelines.

Key actions include:

• Training and Continuous Education: Regularly train regulatory affairs teams on updates in NAFDAC regulations and international guidelines, as they can directly impact operations.
• Quality Management System (QMS): Implement a robust QMS to align with Good Manufacturing Practice (GMP) standards. This will minimize risks associated with product quality and safety.
• Audit Readiness: Maintain audit readiness for both internal reviews and NAFDAC inspections to reassure compliance and align with Good Clinical Practice (GCP).

Utilizing tools such as eversana pharmacovigilance services can enhance your monitoring capabilities, ensuring that your organization remains ahead in compliance adherence.

Conclusion: A Strategic Approach to NAFDAC Regulatory Affairs

Successful navigation of the regulatory landscape in Nigeria requires a thorough understanding of fees, submissions, timelines, and post-approval commitments detailed by NAFDAC. By following these steps, regulatory professionals can effectively strategize their approach to medication approval and market entry in Nigeria.

This comprehensive understanding mitigates risks associated with non-compliance and enhances the potential for successful product launches. Ensure the integration of these practices into your regulatory framework for effective pharma regulatory affairs.